CY1110500T1 - Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας - Google Patents
Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειαςInfo
- Publication number
- CY1110500T1 CY1110500T1 CY20091100826T CY091100826T CY1110500T1 CY 1110500 T1 CY1110500 T1 CY 1110500T1 CY 20091100826 T CY20091100826 T CY 20091100826T CY 091100826 T CY091100826 T CY 091100826T CY 1110500 T1 CY1110500 T1 CY 1110500T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- patients
- new medicines
- chronic
- copper
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αφορά τη χρήση των ενώσεων του γενικού τύπου (I), στον οποίο οι ρίζες R1, R2 και R3 μπορούν να έχουν τις σημασίες που αναφέρονται στις αξιώσεις και στην περιγραφή, για την παραγωγή ενός φαρμάκου για τη θεραπεία της ΧΑΠ (χρόνιας αποφρακτικής πνευμονοπάθειας), καθώς και νέες ενώσεις του γενικού τύπου (I) ως τέτοιες.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10253282A DE10253282A1 (de) | 2002-11-15 | 2002-11-15 | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
EP03778312.3A EP1562603B3 (de) | 2002-11-15 | 2003-11-11 | Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110500T1 true CY1110500T1 (el) | 2015-04-29 |
Family
ID=32185709
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100826T CY1110500T1 (el) | 2002-11-15 | 2009-08-04 | Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας |
CY2014032C CY2014032I2 (el) | 2002-11-15 | 2014-08-13 | Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2014032C CY2014032I2 (el) | 2002-11-15 | 2014-08-13 | Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας |
Country Status (38)
Country | Link |
---|---|
EP (2) | EP1562603B3 (el) |
JP (1) | JP4317138B2 (el) |
KR (1) | KR101092247B1 (el) |
CN (3) | CN101735166A (el) |
AR (2) | AR041969A1 (el) |
AT (1) | ATE430569T1 (el) |
AU (1) | AU2003285326B2 (el) |
BE (1) | BE2014C016I2 (el) |
BR (1) | BRPI0316264B8 (el) |
CA (1) | CA2506082C (el) |
CO (1) | CO5570670A2 (el) |
CY (2) | CY1110500T1 (el) |
DE (2) | DE10253282A1 (el) |
DK (1) | DK1562603T3 (el) |
EA (1) | EA008665B1 (el) |
EC (1) | ECSP055774A (el) |
ES (1) | ES2326878T7 (el) |
FR (1) | FR14C0049I2 (el) |
HR (1) | HRP20050432B1 (el) |
HU (1) | HUS1400011I1 (el) |
IL (1) | IL167900A (el) |
LT (1) | LTC1562603I2 (el) |
LU (1) | LU92433I2 (el) |
ME (1) | ME00354B (el) |
MX (1) | MXPA05005081A (el) |
MY (1) | MY136034A (el) |
NL (1) | NL300650I2 (el) |
NO (2) | NO334314B1 (el) |
NZ (1) | NZ540661A (el) |
PE (1) | PE20040694A1 (el) |
PL (1) | PL212238B1 (el) |
PT (1) | PT1562603E (el) |
RS (1) | RS51607B (el) |
SI (1) | SI1562603T1 (el) |
TW (1) | TWI343812B (el) |
UA (1) | UA81276C2 (el) |
WO (1) | WO2004045618A2 (el) |
ZA (1) | ZA200502246B (el) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
DE102004019539A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von Atemwegserkrankungen |
EP2422786B1 (de) | 2004-04-22 | 2014-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
WO2005110990A1 (de) * | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
DE102004024451A1 (de) * | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
DE102004024454A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
DE102004024452A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation von Betaagonisten |
DE102004024453A1 (de) * | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
US7745621B2 (en) | 2004-05-14 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Long acting bronchodilators for the treatment of respiratory diseases |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
DE102005007654A1 (de) | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
DE102005030733A1 (de) * | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
US20070088160A1 (en) * | 2005-08-15 | 2007-04-19 | Thomas Krueger | Process for the manufacturing of betamimetics |
US20070088030A1 (en) * | 2005-10-10 | 2007-04-19 | Barbara Niklaus-Humke | Aerosol formulations for the inhalation of beta-agonists |
TWI396541B (zh) * | 2005-10-10 | 2013-05-21 | Boehringer Ingelheim Int | 用於治療呼吸疾病之新穎藥物組合 |
PL2532679T3 (pl) | 2005-10-21 | 2017-09-29 | Novartis Ag | Ludzkie przeciwciała przeciwko IL13 i zastosowania terapeutyczne |
EA200801139A1 (ru) * | 2005-11-09 | 2008-10-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция для аэрозольной ингаляции |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2007093608A1 (de) * | 2006-02-16 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
PE20080142A1 (es) | 2006-03-15 | 2008-04-14 | Boehringer Ingelheim Int | Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion |
RU2457209C2 (ru) | 2006-04-21 | 2012-07-27 | Новартис Аг | Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а |
US20100222336A1 (en) * | 2006-08-07 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication |
UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
CN101516885A (zh) | 2006-09-29 | 2009-08-26 | 诺瓦提斯公司 | 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物 |
RU2009120389A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Гетероциклические соединения в качестве противовоспалительных агентов |
ATE493174T1 (de) | 2007-01-10 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer |
EP2125759B1 (de) * | 2007-01-25 | 2011-08-03 | Boehringer Ingelheim International GmbH | Verfahren zur herstellung von betamimetika |
EP2332933A1 (en) | 2007-05-07 | 2011-06-15 | Novartis AG | Epithelial sodium channel (ENaC) inhibitors |
MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
MX2010013675A (es) | 2008-06-10 | 2011-02-15 | Novartis Ag | Derivados de pirazina como bloqueadores del canal de sodio epitelial. |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
ES2442343T3 (es) | 2008-12-30 | 2014-02-11 | Pulmagen Therapeutics (Inflammation) Limited | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios |
PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
AU2010284254B2 (en) | 2009-08-17 | 2015-09-17 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EA024925B1 (ru) * | 2010-09-21 | 2016-11-30 | Интекрин Терапьютикс, Инк. | Антидиабетические твердые фармацевтические композиции |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
ES2551592T3 (es) | 2011-02-25 | 2015-11-20 | Novartis Ag | Pirazolo[1,5-a]piridinas como inhibidores de TRK |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン, エルエルシー | Mtor阻害剤を使用する強化された治療レジメン |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
EP2906218B1 (en) | 2012-10-09 | 2016-12-14 | Boehringer Ingelheim International GmbH | Beta-2-adrenoceptor agonist for the treatment of cough |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
EP3134396B1 (en) | 2014-04-24 | 2019-09-18 | Novartis AG | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
EP3134395B1 (en) | 2014-04-24 | 2018-01-31 | Novartis AG | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
US20200069679A1 (en) | 2016-12-12 | 2020-03-05 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol |
CN110114346B (zh) | 2016-12-20 | 2023-10-31 | Inke股份公司 | 用于制备r-6-羟基-8-[1-羟基-2-[2-(4-甲氧基苯基)-1,1-二甲基乙基氨基乙基]-2h-1,4-苯并噁嗪-3(4h)-酮盐酸盐的改进方法 |
CN108997248B (zh) * | 2018-08-06 | 2023-08-01 | 上海方予健康医药科技有限公司 | 盐酸奥达特罗晶型b及其制备方法 |
CN109096218B (zh) * | 2018-08-06 | 2020-10-27 | 上海方予健康医药科技有限公司 | 盐酸奥达特罗晶型a及其制备方法 |
EP3980121A1 (en) | 2019-06-10 | 2022-04-13 | Novartis AG | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
US20220306617A1 (en) | 2019-08-28 | 2022-09-29 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
CN115768404B (zh) * | 2020-06-09 | 2024-11-08 | 广州谷森制药有限公司 | 含乌美溴铵和三苯乙酸维兰特罗的药物制剂 |
US11331322B1 (en) | 2021-09-15 | 2022-05-17 | Santen Pharmaceutical Co., Ltd. | Medicament for preventing and/or treating dry eye |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3134590A1 (de) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue benzo-heterocyclen |
US4460581A (en) | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
CA2405745A1 (en) * | 2000-04-27 | 2001-11-08 | Boehringer Ingelheim Pharma Kg | New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments |
-
2002
- 2002-11-15 DE DE10253282A patent/DE10253282A1/de not_active Withdrawn
-
2003
- 2003-11-11 AT AT03778312T patent/ATE430569T1/de active
- 2003-11-11 KR KR1020057008679A patent/KR101092247B1/ko active IP Right Grant
- 2003-11-11 CN CN200910266327A patent/CN101735166A/zh active Pending
- 2003-11-11 CN CNA2003801030945A patent/CN1713914A/zh active Pending
- 2003-11-11 SI SI200331634T patent/SI1562603T1/sl unknown
- 2003-11-11 AU AU2003285326A patent/AU2003285326B2/en active Active
- 2003-11-11 ES ES03778312.3T patent/ES2326878T7/es active Active
- 2003-11-11 EP EP03778312.3A patent/EP1562603B3/de not_active Expired - Lifetime
- 2003-11-11 EA EA200500715A patent/EA008665B1/ru active Protection Beyond IP Right Term
- 2003-11-11 EP EP08169872A patent/EP2025338A1/de not_active Withdrawn
- 2003-11-11 DE DE50311502T patent/DE50311502D1/de not_active Expired - Lifetime
- 2003-11-11 DK DK03778312T patent/DK1562603T3/da active
- 2003-11-11 ME MEP-2008-536A patent/ME00354B/me unknown
- 2003-11-11 PL PL375270A patent/PL212238B1/pl unknown
- 2003-11-11 NZ NZ540661A patent/NZ540661A/en not_active IP Right Cessation
- 2003-11-11 UA UAA200505926A patent/UA81276C2/uk unknown
- 2003-11-11 PT PT03778312T patent/PT1562603E/pt unknown
- 2003-11-11 CA CA2506082A patent/CA2506082C/en not_active Expired - Lifetime
- 2003-11-11 WO PCT/EP2003/012565 patent/WO2004045618A2/de active Application Filing
- 2003-11-11 JP JP2004552561A patent/JP4317138B2/ja not_active Expired - Lifetime
- 2003-11-11 RS YU20050361A patent/RS51607B/sr unknown
- 2003-11-11 BR BRPI0316264A patent/BRPI0316264B8/pt active IP Right Grant
- 2003-11-11 CN CN201010004697A patent/CN101817800A/zh active Pending
- 2003-11-11 MX MXPA05005081A patent/MXPA05005081A/es active IP Right Grant
- 2003-11-13 PE PE2003001147A patent/PE20040694A1/es active IP Right Grant
- 2003-11-13 MY MYPI20034360A patent/MY136034A/en unknown
- 2003-11-14 TW TW092132031A patent/TWI343812B/zh active
- 2003-11-14 AR ARP030104201A patent/AR041969A1/es active Pending
-
2005
- 2005-03-17 ZA ZA2005/02246A patent/ZA200502246B/en unknown
- 2005-04-07 IL IL167900A patent/IL167900A/en active Protection Beyond IP Right Term
- 2005-05-02 EC EC2005005774A patent/ECSP055774A/es unknown
- 2005-05-13 HR HR20050432A patent/HRP20050432B1/xx not_active IP Right Cessation
- 2005-06-14 CO CO05057641A patent/CO5570670A2/es not_active Application Discontinuation
- 2005-06-14 NO NO20052883A patent/NO334314B1/no not_active IP Right Cessation
-
2009
- 2009-08-04 CY CY20091100826T patent/CY1110500T1/el unknown
-
2012
- 2012-07-19 AR ARP120102613A patent/AR087241A2/es active Pending
-
2014
- 2014-02-27 BE BE2014C016C patent/BE2014C016I2/fr unknown
- 2014-03-06 LT LTPA2014012C patent/LTC1562603I2/lt unknown
- 2014-03-07 NL NL300650C patent/NL300650I2/nl unknown
- 2014-03-07 HU HUS1400011C patent/HUS1400011I1/hu unknown
- 2014-03-10 NO NO2014005C patent/NO2014005I1/no unknown
- 2014-04-22 LU LU92433C patent/LU92433I2/fr unknown
- 2014-06-23 FR FR14C0049C patent/FR14C0049I2/fr active Active
- 2014-08-13 CY CY2014032C patent/CY2014032I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110500T1 (el) | Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας | |
SE0102299D0 (sv) | Compounds | |
SE0102300D0 (sv) | Compounds | |
CY1114728T1 (el) | Φαρμακοτεχνικη μορφη εισπνοης περιλαμβανουσα παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου | |
CY1111022T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
CY1108267T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
CY1113039T1 (el) | Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο | |
IS2696B (is) | Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð | |
CY1115350T1 (el) | Χρησεις αναστολεων της dpp iv | |
CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
CY1111670T1 (el) | Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων | |
DE602005026007D1 (de) | Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd) | |
EA200501274A1 (ru) | Пиразолы и способы их получения и применения | |
CY1108813T1 (el) | Αναστολεις κινασων τυροσινης | |
CY1112495T1 (el) | Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης | |
CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
CY1107985T1 (el) | Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου | |
CY1108843T1 (el) | 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων | |
CY1107945T1 (el) | Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β | |
CY1111197T1 (el) | Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων | |
IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
CY1108324T1 (el) | Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης | |
EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
NO20073839L (no) | Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette |